168 related articles for article (PubMed ID: 30774430)
1. Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense.
Zhang J; Geng H; Liu L; Zhang H
Cancer Manag Res; 2019; 11():1023-1032. PubMed ID: 30774430
[TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia.
Shi Y; Xu D; Xu Y; Shen H; Zhang Y; Ye X; Jin J; Cui D; Xie W
J Oncol; 2022; 2022():9005804. PubMed ID: 36081666
[TBL] [Abstract][Full Text] [Related]
4. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F; Li D; Li G; Cheng C; Wei X
Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
[TBL] [Abstract][Full Text] [Related]
5. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.
Meng HT; Li L; Liu H; Wang Y; Li GC; Qian WB
Acta Pharmacol Sin; 2009 Nov; 30(11):1529-36. PubMed ID: 19820719
[TBL] [Abstract][Full Text] [Related]
9. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
Zhou H; Xu RZ; Gu Y; Shi PF; Qian S
Leuk Lymphoma; 2020 May; 61(5):1084-1096. PubMed ID: 29334312
[TBL] [Abstract][Full Text] [Related]
10. The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance.
Manna A; De Sarkar S; De S; Bauri AK; Chattopadhyay S; Chatterjee M
Phytomedicine; 2015 Jul; 22(7-8):713-23. PubMed ID: 26141757
[TBL] [Abstract][Full Text] [Related]
11. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1].
Shen JP; Yang H; Ni WM; Qian WB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):485-90. PubMed ID: 23086639
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
[TBL] [Abstract][Full Text] [Related]
14. The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia.
Shi Y; Ye J; Yang Y; Zhao Y; Shen H; Ye X; Xie W
Front Oncol; 2021; 11():692497. PubMed ID: 34336680
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis.
Zhang J; Chen B; Wu T; Wang Q; Zhuang L; Zhu C; Fan N; Qing W; Ma Y; Xu X
PLoS One; 2015; 10(11):e0142422. PubMed ID: 26544558
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.
Cai Z; Lin M; Wuchter C; Ruppert V; Dörken B; Ludwig WD; Karawajew L
Leukemia; 2001 Apr; 15(4):567-74. PubMed ID: 11368358
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions.
Guo D; Zhu L; Huang Z; Zhou H; Ge Y; Ma W; Wu J; Zhang X; Zhou X; Zhang Y; Zhao Y; Gu N
Biomaterials; 2013 Oct; 34(32):7884-94. PubMed ID: 23876760
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
19. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
20. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun.
Alhuthali HM; Bradshaw TD; Lim KH; Kam TS; Seedhouse CH
BMC Cancer; 2020 Jul; 20(1):629. PubMed ID: 32635894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]